We have previously shown that docosahexaenoic acid (DHA) significantly reduced L-Dopa-induced dyskinesia (LID) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys (Samadi et al., Ann. Neurol. 59:282-288, 2006). In the present study, we measured for the first time mRNA levels of Nur77, an orphan nuclear receptor that participates to adaptive and/or aberrant dopamine-related behaviors, and retinoid X receptor γ1 (RXRγ1), a putative brain receptor for DHA and transcriptional partner of Nur77, in MPTP monkeys treated with L-Dopa and DHA. The RXRγ1 mRNA is strongly expressed in monkey caudate nucleus and putamen, but no change in levels of RXRγ1 was observed following MPTP and L-Dopa treatments. On the other hand, denervation reduced Nur77 mRNA levels, whereas chronic L-Dopa treatment strongly induced Nur77 transcripts. These modulations are taking place in substance P positive cells and are associated with both caudate-putamen matrix and striosome compartments. Interestingly, combination of L-Dopa with DHA further increases Nur77 mRNA levels in the anterior caudate-putamen, and mainly in striosomes. This is accompanied by a significant inverse correlation between Nur77 mRNA levels and dyskinetic scores. Taken together, our results show that Nur77 expression is modulated following dopamine denervation and chronic L-Dopa therapy in a non-human primate model of Parkinson's disease, and suggest that strong modulation of Nur77 expression might be linked to a reduced risk to develop LIDs.
Introduction
Levodopa (L-Dopa) therapy is the most common treatment for Parkinson's disease (PD). However, in a large proportion of individuals, therapy is hampered by the development of motor complications such as fluctuations, shortening of the motor response (also called wearing off) and dyskinesias. L-Dopa-induced dyskinesia (LID) is an important motor complication of chronic L-Dopa administration, with a prevalence ranging from 45 to 85% (Brotchie et al., 2005) . The development of LIDs over time is a complex process that remains only partially understood, for review see Brotchie et al. (2005 ), Calabresi et al. (2008 ), Cenci (2007 . Importantly, once the brain is primed to elicit dyskinesias, it is difficult to treat parkinsonian symptoms without inducing dyskinesias. LIDs are also extremely difficult to reduce or reverse once they have appeared. In fact, LID can become so severely disabling as to negate any clinical benefit from dopaminergic therapy in advanced PD patients.
Non human primates intoxicated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin develop a parkinsonian-like syndrome that is very similar to motor symptoms associated with PD in humans. This model also allows insights about molecular changes taking place subsequently to dopamine neuron loss and further treatment. In addition, this parkinsonian primate model has been proven to mimic particularly well both the initial characteristic of L-Dopa behavioral response and the development of long-term motor complications, such as LID (Calon et al., 2000) .
LIDs can be assimilated to a form of pathological learning or plasticity (Bédard et al., 1999; Cenci, 2007) . Their delayed appearance and persistence after treatment cessation strongly suggest that longterm and possibly permanent basal ganglia circuitry alterations are involved. Therefore, transcription factors, which regulate gene expression, are likely to be involved in these molecular processes. Indeed, chronic Fos proteins of the ΔFosB family of transcription factors in the caudate-putamen, which, when coupled with Jun-D, form AP-1 complexes that can modulate the expression of several genes associated with the generation of LIDs in rodent and primate Neurobiology of Disease 36 (2009) 213-222 
